Growth Metrics

Lineage Cell Therapeutics (LCTX) Intangibles: 2010-2025

Historic Intangibles for Lineage Cell Therapeutics (LCTX) over the last 13 years, with Sep 2025 value amounting to $31.7 million.

  • Lineage Cell Therapeutics' Intangibles fell 52.07% to $31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.7 million, marking a year-over-year decrease of 52.07%. This contributed to the annual value of $46.5 million for FY2024, which is 0.05% down from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Intangibles stood at $31.7 million for Q3 2025, which was down 0.00% from $31.7 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' Intangibles' 5-year high stood at $66.1 million during Q1 2021, with a 5-year trough of $31.7 million in Q2 2025.
  • In the last 3 years, Lineage Cell Therapeutics' Intangibles had a median value of $66.1 million in 2024 and averaged $54.5 million.
  • Data for Lineage Cell Therapeutics' Intangibles shows a maximum YoY crashed of 52.07% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows Lineage Cell Therapeutics' Intangibles stood at $66.1 million in 2021, then remained steady at $66.1 million in 2022, then remained steady at $46.6 million in 2023, then dropped by 0.05% to $46.5 million in 2024, then plummeted by 52.07% to $31.7 million in 2025.
  • Its Intangibles was $31.7 million in Q3 2025, compared to $31.7 million in Q2 2025 and $46.5 million in Q1 2025.